Cipla

The director of Cipla, a $ 325 million Indian pharmaceutical company and seller of inexpensive AIDS drugs in South Africa, must decide what to do with Cipla’s future. With India poised to enforce international patents in just two years, much of Cipla’s product range could become unworkable (as it relies on protected product patents in developed countries). He describes Cipla’s role in forcing global pharmaceutical companies to cut the prices of AIDS drugs.

We don‘t have the case solution, but we pay up to $50 for yours!

• Set a reminder to receive an email after your university‘s case study deadline.
• Upload your case study solution. We will review it for quality.
• Get your money via PayPal or to your bank account.